IDK® Zonulin (Stool) ELISA

Article number: KR5600



Pack size

96 Tests

Standard concentrations included in the kit

0.25-16 ng/ml

Possible sample matrix and volumes

Stool 15 mg

Incubation periods

  1. 1 hour
  2. 1 hour
  3. 10-20 minutes


Regulatory Status

outside EU: RUO (research use only)

This ELISA is intended for the quantitative determination of zonulin family peptides (ZFP) in stool. For in vitro diagnostic use only.

Zonulin is a human protein analogue to the zonula occludens toxin derived from Vibrio cholerae which regulates tight junctions of the digestive tract. Zonulin binds to a specific receptor on the surface of intestinal epithelia and triggers a cascade of biochemical events which induces tight junction disassembly and a subsequent permeability increase of the intestinal epithelia, allowing some substances to pass through and activate immune reactions.
Fasano and his co-workers found that the zonulin system is more activated in celiac disease and type 1 diabetes mellitus patients. Patients with active celiac disease showed higher levels of zonulin and anti-zonulin antibodies compared to non-celiac patients and patients in remission, who were on a gluten-free diet.
An increased intestinal permeability, also colloquially called leaky gut, is nowadays associated with the metabolic syndrome, obesity, and several autoimmune, inflammatory, and neoplastic diseases. Based on evidence, leaky gut plays a meaningful role in diseases such as multiple sclerosis, rheumatoid arthritis, asthma, and inflammatory bowel diseases.
The polyclonal anti-body used in our ELISA is based on the zonulin sequence as published by Wang (Journal of Cell Science, 2000) and di Pierro (Journal of Biological Chemistry, 2001).
Correspondingly, the readings of IDK® Zonulin ELISA detecting zonulin family peptides correlate well - as already found in many papers - with established metabolic traits linked to increased gut permeability, such as insulin resistance and obesity.